Vikram Patel Awarded Prestigious John Dirks Canada Gairdner Global Health Award

IMT News Desk
IMT News Desk
· 2 min read
Imaging
The Gairdner Foundation today announced the 2019 Canada Gairdner Award laureates, recognising Goa and Boston-based Vikram Patel, Ph.D., F. Med.Sci., for his research career raising the global profile of mental health problems. Prof Patel has been awarded the 2019 John Dirks Canada Gairdner Global Health Award for his world-leading research in global mental health, generating knowledge on the burden and determinants of mental health problems in low-and middle-income countries and pioneering approaches for the prevention and treatment of mental health in low-resource settings.
Each year seven Canada Gairdner Awards are presented to honour the world’s most significant biomedical and global health researchers. The John Dirks Canada Gairdner Global Health Award recognizes a contribution to health in the developing world. Laureates receive a $100,000 cash honorarium and will be formally presented with their awards on October 24, 2019 at the annual Canada Gairdner Awards Gala in Toronto.
“This prize is a recognition of the tremendous effort of innovators in low resource settings to transform our understanding of mental health problems and to innovate ways in which we can address these problems in contexts where there are very few resources,” said Prof. Vikram Patel.
Prof. Patel is the Pershing Square Professor of Global Health and Wellcome Trust Principal Research Fellow, Department of Global Health and Social Medicine, Harvard Medical School; Professor, Harvard TH Chan School of Public Health; Honorary Professor of Global Mental Health, Centre for Global Mental Health, London School of Hygiene & Tropical Medicine; Adjunct Professor, Centre for Chronic Conditions and Injuries, Public Health Foundation of India, New Delhi; Co-founder, Sangath, India
Prof. Patel has dedicated his research career to raising the global profile of mental health problems through: epidemiological research demonstrating the burden of mental disorders in low and middle-income countries, their strong association with poverty and with other public health priorities, such as HIV and child growth and development; and intervention research in which he has applied a systematic approach to the design, delivery and evaluation of contextually appropriate psychosocial interventions provided by lay and community health providers. This has included the primary care treatment of depression, anxiety and alcohol use disorders, the community-based care of people with schizophrenia and autism, and the prevention and treatment of adolescent mental health problems through school-based interventions.

Read Next

Akums Reports Strong Q4 FY26 Performance; EBITDA Surges 62%, Board Recommends Dividend
News
May 15, 2026

Akums Reports Strong Q4 FY26 Performance; EBITDA Surges 62%, Board Recommends Dividend

Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organisation (CDMO), has reported a robust financial performance for the fourth quarter and full year ended March 31, 2026, driven by strong growth in its core CDMO business and improved operational efficiencies. Q4 FY26: Profitability Outpaces Revenue Growth Akums posted an operating revenue of […]
Article by: IMT News Desk
Alembic Pharmaceuticals announces USFDA Tentative Approval for Darolutamide Tablets
News
May 14, 2026

Alembic Pharmaceuticals announces USFDA Tentative Approval for Darolutamide Tablets

Alembic Pharmaceuticals Limited (Alembic) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darolutamide Tablets, 300 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nubeqa Tablets, 300 mg, of Bayer HealthCare Pharmaceuticals Inc. (Bayer). Darolutamide is an androgen […]
Article by: IMT News Desk
Lilly launches Lormalzi® (Donanemab) for the treatment of early symptomatic Alzheimer’s Disease in India
News
May 14, 2026

Lilly launches Lormalzi® (Donanemab) for the treatment of early symptomatic Alzheimer’s Disease in India

Eli Lilly and Company (India) Pvt. Ltd. has announced the launch of Lormalzi® (donanemab, 350 mg/20 mL IV vial) in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for the treatment of Alzheimer’s disease with mild cognitive impairment or those in the mild dementia stage of disease. Lormalzi® is the first […]
Article by: IMT News Desk
Stryker and Max Smart Hospital, Saket Partner to Advance Surgeon Training and Education in Robotic-Arm Assisted Joint Replacement
News
May 14, 2026

Stryker and Max Smart Hospital, Saket Partner to Advance Surgeon Training and Education in Robotic-Arm Assisted Joint Replacement

Stryker and Max Smart Super Speciality Hospital, Saket, announced a strategic collaboration to advance surgeon training, clinical education, and patient care in robotic-arm-assisted joint replacement in India. As part of this collaboration, Max Smart Super Speciality Hospital, Saket, will serve as a training and education center for orthopaedics. The collaboration aims to support the evolving joint replacement ecosystem […]
Article by: IMT News Desk